KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Change in Acquisitions & Divestments (2016 - 2025)

Historic Change in Acquisitions & Divestments for Travere Therapeutics (TVTX) over the last 13 years, with Q3 2025 value amounting to $106.6 million.

  • Travere Therapeutics' Change in Acquisitions & Divestments rose 9629.22% to $106.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $296.2 million, marking a year-over-year decrease of 780.02%. This contributed to the annual value of $326.3 million for FY2024, which is 246.31% down from last year.
  • Travere Therapeutics' Change in Acquisitions & Divestments amounted to $106.6 million in Q3 2025, which was up 9629.22% from $81.4 million recorded in Q2 2025.
  • Travere Therapeutics' 5-year Change in Acquisitions & Divestments high stood at $152.6 million for Q2 2022, and its period low was $50.0 million during Q4 2023.
  • Its 5-year average for Change in Acquisitions & Divestments is $90.4 million, with a median of $89.7 million in 2021.
  • In the last 5 years, Travere Therapeutics' Change in Acquisitions & Divestments skyrocketed by 21005.03% in 2021 and then plummeted by 5753.58% in 2022.
  • Over the past 5 years, Travere Therapeutics' Change in Acquisitions & Divestments (Quarter) stood at $57.5 million in 2021, then dropped by 8.91% to $52.4 million in 2022, then dropped by 4.55% to $50.0 million in 2023, then grew by 10.1% to $55.0 million in 2024, then surged by 93.69% to $106.6 million in 2025.
  • Its Change in Acquisitions & Divestments was $106.6 million in Q3 2025, compared to $81.4 million in Q2 2025 and $53.2 million in Q1 2025.